Latest news
FDA Grants Breakthrough Therapy Status to a Pancreatic Cancer Drug for a Mutation Found in Roughly 1 in 50 Patients - medicaldaily.commedicaldaily.com · Thu, 06 Aug 2026 12:50:07 GMTOcugen Reports Q2 2026 Results, Advances OCU410 Phase 3, Secures RMAT Designation and $130 Million Financing - Quiver QuantitativeQuiver Quantitative · Thu, 06 Aug 2026 11:15:00 GMTFDA Grants Breakthrough Therapy Designation to Olomorasib for KRAS G12C-Mutant Advanced Pancreatic Cancer - OncodailyOncodaily · Wed, 05 Aug 2026 13:26:29 GMTLexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation For LX2020 For The Treatment Of PKP2 Arrhythmogenic Cardiomyopathy - marketscreener.commarketscreener.com · Wed, 05 Aug 2026 11:00:00 GMTFDA grants breakthrough therapy designation to Lilly’s olomorasib - Pharmaceutical Business review -Pharmaceutical Business review - · Tue, 04 Aug 2026 19:15:28 GMTFDA Grants Breakthrough Therapy Status to Eli Lilly's Pancreatic Cancer Treatment - Investing News NetworkInvesting News Network · Tue, 04 Aug 2026 18:53:00 GMTOlomorasib Earns FDA Breakthrough Therapy in KRAS G12C+ Pancreatic Cancer - CancerNetworkCancerNetwork · Tue, 04 Aug 2026 15:38:44 GMTLilly’s olomorasib gets FDA Breakthrough Therapy designation for pancreatic cancer - PMLiVEPMLiVE · Tue, 04 Aug 2026 10:55:00 GMT